Tokyo, July 7 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000058372) titled 'Efficacy of immune checkpoint inhibitors in patients with MSI-H/dMMR small bowel adenocarcinoma' on July 7.
Study Type:
Others,meta-analysis etc
Primary Sponsor:
Institute - Toyohashi Municipal Hospital
Condition:
Condition - MSI-H/dMMR small bowel adenocarcinoma
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - Meta-analysis of the efficacy of immune checkpoint inhibitors in MSI-H/dMMR small bowel adenocarcinoma
Basic objectives2 - Efficacy
Eligibility:
Age-lower limit - Not applicable
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - (1) The search terms include "small bowel adenocarcinoma", "non-colorectal", "solid tumor", "MSI-H", "dMMR", "immunotherapy", "immune checkpoint", "programmed cell death protein 1", "programmed cell death ligand 1 inhibitor", "PD-1" and "PD-L1".
(2) Single-arm Phase I-III clinical trials evaluating immunotherapy in patients with advanced SBA or solid tumors, reporting objective response rates or treatment outcomes for individual patients.
Key exclusion criteria - (1) Observational or retrospective studies.
(2) Systematic review or meta-analysis studies.
(3) Studiers published in languages other than English.
(6) Conference abstracts.
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2025 Year 07 Month 07 Day
Anticipated trial start date - 2025 Year 07 Month 07 Day
Last follow-up date - 2025 Year 07 Month 07 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000066733
Disclaimer: Curated by HT Syndication.
